Lovastatin in X-Linked Adrenoleukodystrophy
Authors:
- Marc EngelenMEMarc Engelen
- Rob OfmanRORob Ofman
- Marcel G.W. DijkgraafMDMarcel G.W. Dijkgraaf
- Michiel HijzenMHMichiel Hijzen
- Lucinda A. van der WardtLWLucinda A. van der Wardt
- Bjorn M. van GeelBGBjorn M. van Geel
- Marianne de VisserMVMarianne de Visser
- Ronald J.A. WandersRWRonald J.A. Wanders
- Bwee Tien Poll-TheBPBwee Tien Poll-The
- Stephan KempSKStephan Kemp
- 21 January 2010
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (3) , 276-277
Abstract
As reported previously in the Journal, lovastatin lowers levels of very-long-chain fatty acids in plasma in patients with X-linked adrenoleukodystrophy (X-ALD).1 Further studies did not reproduce this finding with the use of simvastatin in patients or with the use of lovastatin in X-ALD–knockout mice.2,3 Still, many patients with X-ALD worldwide receive lovastatin.Keywords
This publication has 5 references indexed in Scilit:
- Analysis of very long-chain fatty acids using electrospray ionization mass spectrometryMolecular Genetics and Metabolism, 2003
- Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy miceFEBS Letters, 2000
- Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophyAnnals of Neurology, 2000
- Lovastatin for X-Linked AdrenoleukodystrophyNew England Journal of Medicine, 1998
- Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy.Journal of Clinical Investigation, 1995